Abstract
Anlotinib, a novel oral small molecule multi-target TKI for potently targeting VEGFR, FGFR, PDGFR and c-Kit, has dual effects of anti-tumor angiogenesis and inhibition of tumor growth. The positive phase III trial (ALTER0303) showed anlotinib improved both progression-free survival (PFS) and overall survival (OS) survival as a single agent in third-line treatment of advanced non-small cell lung cancer (NSCLC). Here, ALTER-L018 is aimed to assess efficacy and safety of anlotinib plus docetaxel in patients with refractory advanced NSCLC whose disease had progressed during or after first-line platinum-based chemotherapy with or without Immune checkpoint inhibitors treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
